Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Four days/week antiretroviral maintenance strategy (ANRS 170 QUATUOR): substudies of reservoirs and ultrasensitive drug resistance.
Lambert-Niclot S, Abdi B, Bellet J, Fofana D, De Truchis P, Amat K, Alvarez JC, Surgers L, Allavena C, Zaegell-Faucher O, Morlat P, Palich R, Gibowski S, Costagliola D, Girard PM, Landman R, Assoumou L, Morand-Joubert L; ANRS 170 QUATUOR study group. Lambert-Niclot S, et al. Among authors: abdi b. J Antimicrob Chemother. 2023 Jun 1;78(6):1510-1521. doi: 10.1093/jac/dkad119. J Antimicrob Chemother. 2023. PMID: 37104815
Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy.
Soulie C, Santoro MM, Storto A, Abdi B, Charpentier C, Armenia D, Jary A, Forbici F, Bertoli A, Gennari W, Andreoni M, Mussini C, Antinori A, Perno CF, Calvez V, Ceccherini-Silberstein F, Descamps D, Marcelin AG. Soulie C, et al. Among authors: abdi b. J Antimicrob Chemother. 2020 Apr 1;75(4):1026-1030. doi: 10.1093/jac/dkz553. J Antimicrob Chemother. 2020. PMID: 31976534 Free article.
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
Soulie C, Assoumou L, Abdi B, Sayon S, Nguyen T, Valantin MA, Beniguel L, Ferre V, Alloui C, Montes B, Avettand-Fenoel V, Delaugerre C, Descamps D, Martinez E, Reynes J, Peytavin G, Costagliola D, Katlama C, Calvez V, Marcelin AG; ANRS-163 ETRAL study group. Soulie C, et al. Among authors: abdi b. J Antimicrob Chemother. 2020 Jul 1;75(7):1943-1949. doi: 10.1093/jac/dkaa090. J Antimicrob Chemother. 2020. PMID: 32259255 Clinical Trial.
Persistent low-level viraemia in antiretroviral treatment-experienced patients is not linked to viral resistance or inadequate drug concentrations.
Palich R, Wirden M, Peytavin G, Lê MP, Seang S, Abdi B, Schneider L, Tubiana R, Valantin MA, Paccoud O, Soulié C, Calvez V, Katlama C, Marcelin AG. Palich R, et al. Among authors: abdi b. J Antimicrob Chemother. 2020 Oct 1;75(10):2981-2985. doi: 10.1093/jac/dkaa273. J Antimicrob Chemother. 2020. PMID: 32642769
Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
Palich R, Abdi B, Wirden M, Lourida G, Tubiana R, Faycal A, Valantin MA, Schneider L, Seang S, Agher R, Simon A, Soulie C, Le MP, Peytavin G, Calvez V, Marcelin AG, Katlama C. Palich R, et al. Among authors: abdi b. J Antimicrob Chemother. 2021 Jun 18;76(7):1893-1897. doi: 10.1093/jac/dkab108. J Antimicrob Chemother. 2021. PMID: 33855355 Free article.
The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients.
Teyssou E, Soulie C, Visseaux B, Lambert-Niclot S, Ferre V, Marot S, Jary A, Sayon S, Zafilaza K, Leducq V, Schnuriger A, Abdi B, Wirden M, Houhou-Fidouh N, Charpentier C, Morand-Joubert L, Burrel S, Descamps D, Calvez V, Marcelin AG. Teyssou E, et al. Among authors: abdi b. J Infect. 2021 Jul;83(1):119-145. doi: 10.1016/j.jinf.2021.04.023. Epub 2021 Apr 28. J Infect. 2021. PMID: 33932451 Free PMC article. No abstract available.
70 results